Novel agents for managing dyslipidaemia

Expert Opinion on Investigational Drugs

Volumn 10, Issue 11, 2001, Pages 1901-1911

  Best, J D ^a   Jenkins, A J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ABC A1 upregulation; ACAT inhibitor; AMP kinase agonist; Anti oxidants; CETP inhibitor; Cholesterol absorption inhibitor; Fibrate; HDL cholesterol; HMG CoA reductase inhibitor; LDL cholesterol; LXR agonist; MTP binding antagonist; PPAR agonist; RXR agonist; Squalene synthase inhibitor; SR B1 receptor agonist

Indexed keywords

ADENYLATE KINASE AGONIST; ALPHA TOCOTRIENOL; ANTILIPEMIC AGENT; ATORVASTATIN; AVASIMIDE; BENZOTHIOPYRANOINDOLE; BMS 187745; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CL 1011; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYTOCHROME P450; ESTROGEN DERIVATIVE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOXYGENASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PITAVASCTATIN; PITAVASTATIN; PROTEIN INHIBITOR; RETINOID X RECEPTOR; RETINOID X RECEPTOR AGONIST; ROSUVASTATIN; SIMVASTATIN; SQUALENE SYNTHASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MANAGEMENT; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MOUSE; NONHUMAN; OBESITY; PHASE 3 CLINICAL TRIAL; PREDICTION; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; APOLIPOPROTEINS B; CHOLESTEROL; CLINICAL TRIALS; HUMANS; HYPERLIPIDEMIAS; TRIGLYCERIDES;

EID: 0035169543     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.11.1901     Document Type: Review

References (100)

1. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations
2. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010
3. The epidemiology and management of diabetes mellitus in Indonesia
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels
8. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol
9. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
10. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomised controlled trial
11. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
12. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
13. Cholesterol lowering in atherosclerosis
14. HMG-CoA reductase inhibitors: Assessing differences in drug interactions and safety profiles
15. Statin therapy and reductions in low-density lipoprotein cholesterol: Initial clinical data on the potent new statin rosuvastatin
16. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
17. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: Comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors
18. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species
19. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers
20. Colesevelam hydrochloride: A non-absorbed, polymeric cholesterol-lowering agent
21. Xo1 INXS: Role of the liver X and the farnesol X receptors
22. +/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits
23. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): Pooled analysis of two phase II studies
24. Ezetimibe reduces plasma cholesterol and inhibits the development of atherosclerosis in ApoE knockout mice with and without LDL receptors
25. Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol
26. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype
27. ABCA1. The gatekeeper for eliminating excess tissue cholesterol
28. ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism
29. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers
30. Role of LXRs in control of lipogenesis
31. Lifibrol: First member of a new class of lipid-lowering drugs?
32. Lifibrol: A novel lipid-lowering drug for the therapy of hypercholesterolemia
33. HDL steady state levels are not affected, but HDL ApoA1 turnover is enhanced by lifibrol in patients with hypercholesterolaemia and mixed hyperlipidaemia
34. Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol
35. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
36. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol and Recurrent Events
37. Relation of gemfibrozil treatment and lipid levels with major coronary events: VAHIT: A randomised controlled trial
38. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial
39. An overview of reverse cholesterol transport
40. Pros and cons of inhibiting cholesteryl ester transfer protein
41. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein
42. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
43. Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesteryl ester transfer protein
44. Peroxisome proliferator-activated receptors: From genes to physiology
45. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
46. A potent PPAR alpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle
47. Novel approaches to treating cardiovascular disease: Lessons from Tangier disease
48. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha
49. Sterol-dependent transactivation of the ABCA1 promoter by the liver X receptor/retinoid X receptor
50. PPAR-α and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
51. RXR agonists activate PPARα-inducible genes, lower triglycerides, and raise HDL levels in vivo
52. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor
53. Bexarotene ligand pharmaceuticals
54. Central hypothyroidism associated with retinoid X receptor-selective ligands
55. Identification of scavenger receptor SR-B1 as a high density lipoprotein receptor
56. CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins
57. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B Type 1 results in selective sorting of HDL cholesterol from protein and polarised cholesterol secretion
58. Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type1-deficient mice
59. Gene transfer and hepatic overexpression of the HDL receptor SR-B1 reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse
60. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000
61. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
62. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women
63. Raloxifene reduces atherosclerosis: Studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits
64. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys
65. The effect of isoflavones extracted from red clover (Rimostil) on lipid metabolism
66. Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
67. Lipoprotein cholesterol, apolipoprotein A1 and B and lipoprotein (a) abnormalities in men with premature coronary heart disease
68. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease
69. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
70. 2000 George Lyman Duff Memorial Lecture: Atherosclerosis is a liver disease of the heart
71. Analysis of the role of microsomal triglyceride transfer protein in the tissue-specific knockout mouse
72. Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B
73. Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist
74. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors
75. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study
76. Epidemiology of hypertriglyceridemia and cardiovascular disease
77. Evidence that triglycerides are an independent coronary heart disease risk factor
78. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
79. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary heart disease: The Bezafibrate Infarction Prevention (BIP) Study
80. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: Further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial
81. Acyl coenzyme A: Cholesterol acyltransferase types 1 and 2: Structure and function in atherosclerosis
82. NTE-122, an acyl-coa: Cholesterol acyltransferase inhibitor, prevents the progression of atherogenesis in cholesterol-fed rabbits
83. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression
84. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages
85. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia
86. Effect of the acyl-CoA: Cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans
87. Dealing with energy demand: The AMP-activated protein kinase
88. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats
89. LDL oxidation and its pathophysiologic significance
90. Oxidized phospholipids and isoprostanes in atherosclerosis
91. Oxysterols and atherosclerosis
92. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
93. Vitamin E supplementation and cardiovascular events in high-risk patients
94. Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study design
95. Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience
96. Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling
97. Protection of low density lipoprotein oxidation by the antioxidant agent IRFI005, a new synthetic hydrophilic vitamin E analogue
98. Anti-atherogenic effect of citrus flavonoids, naringen and naringenin, associated with hepatic acat and aortic vcam-1 and mcp-1 in high cholesterol-fed rabbits
99. Phenolic antioxidants: A rationale for design and evaluation of novel antioxidant drug for atherosclerosis
100. 15-Lipoxygenase and its inhibition: A novel target for vascular disease